- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 90,840 | 05.06.24 12:59:36 | +0,360 | +0,40% | 0,000 | 0,000 | 90,540 | 90,480 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 920,000 | 05.06.24 10:07:49 | +7,400 | +0,81% | 0,000 | 0,000 | 910,000 | 912,600 |
